drugset
Drugs / Tebotelimab
last change Mar 2025 re-read 2 minutes ago

Tebotelimab

also known as MGD013 · Mgd013 (pd-1 x lag-3)

Protein / enzyme biologic targets LAG3, PDCD1 via inhibition

Developed for
head and neck squamous cell carcinoma · gastric cancer · triple-negative breast carcinoma · biliary tract cancer · cervical cancer · cholangiocarcinoma · endometrial carcinoma · gastroesophageal junction adenocarcinoma
+6 more · hematopoietic and lymphoid cell neoplasm · hepatocellular carcinoma · metastatic melanoma · non-small cell lung carcinoma · ovarian cancer · small cell lung carcinoma
Investigated by
MacroGenics · Zai Lab (Shanghai) Co., Ltd.

Trials 7 · a red edge is where a trial was stopped

today NCT04634825 · Ph 2 NCT04653038 · Ph 1 NCT04212221 · Ph 1/2 NCT04178460 · Ph 1 NCT04129320 · Ph 2/3 NCT04082364 · Ph 2/3 NCT03219268 · Ph 1
201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT04653038 Oct 2020 → Mar 2022 metastatic melanoma Zai Lab (Shanghai) Co., Ltd. Terminated No outcome recorded
Phase 1 NCT04178460 Feb 2020 → Mar 2022 biliary tract cancer, endometrial carcinoma, gastric cancer, triple-negative breast carcinoma Zai Lab (Shanghai) Co., Ltd. Terminated No outcome recorded
Phase 1 NCT03219268 Aug 2017 → Feb 2023 cervical cancer, cholangiocarcinoma, head and neck squamous cell carcinoma, hematopoietic and lymphoid cell neoplasm +4 MacroGenics Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT04212221 Apr 2020 → Apr 2022 hepatocellular carcinoma Zai Lab (Shanghai) Co., Ltd. Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT04634825 Mar 2021 → Jul 2022 head and neck squamous cell carcinoma MacroGenics Terminated No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT04129320 Oct 2019 → Oct 2020 head and neck squamous cell carcinoma MacroGenics Withdrawn No outcome recorded
Phase 2/3 NCT04082364 Sep 2019 → Jan 2024 gastric cancer, gastroesophageal junction adenocarcinoma MacroGenics Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as tebotelimab ClinicalTrials.gov intervention name — accepted as the source's own label NCT03219268 ↗
2

NCT04634825 ↗

NCT04082364 ↗
Known as MGD013 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04212221 ↗
3

NCT04653038 ↗

NCT04129320 ↗

NCT04178460 ↗
Known as Mgd013 (pd-1 x lag-3) ChEMBL registry synonym — accepted as the source's own label CHEMBL4594578 ↗
Action Inhibit “a bispecific PD-1×LAG-3 DART molecule that blocks both PD-1 and LAG-3” PMID 37857711 ↗ Oct 2023
2

“Lymphocyte activation gene 3 protein inhibitor” CHEMBL4594578 ↗

“Programmed cell death protein 1 inhibitor” CHEMBL4594578 ↗
Modality Protein / enzyme biologic “Tebotelimab, a bispecific PD-1×LAG-3 DART molecule” PMID 37857711 ↗ Oct 2023
Route Intravenous “1 mg IV every other week” NCT03219268 ↗
Target LAG3 “Lymphocyte activation gene 3 protein inhibitor” CHEMBL4594578 ↗
Target PDCD1 “Programmed cell death protein 1 inhibitor” CHEMBL4594578 ↗